InsiderTrades.com logo
Mark W. Hahn net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mark Hahn Biography and Net Worth

CFO of Verona Pharma PLC American Depositary Share
From January 2018 until its acquisition by Swedish Orphan Biovitrum for up to $915 million in November 2019, Mr Hahn served as CFO of Dova Pharmaceuticals, a US company developing therapeutics for rare diseases, where he was instrumental in raising capital and in the launch of Dova’s first commercial product. From 2010 until its acquisition by Melinta Therapeutics in November 2017, Mr Hahn was CFO of Cempra where he led the company’s IPO and several subsequent follow-on offerings. Prior to Cempra, Mr Hahn was the CFO of several other public and private companies. Mr Hahn began his career at Ernst & Young. He received a Bachelor of Business Administration degree in Accounting and Finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina.

What is Mark W. Hahn's net worth?

The estimated net worth of Mark W. Hahn is at least $1.33 billion as of August 1st, 2025. Mr. Hahn owns 12,464,968 shares of Verona Pharma PLC American Depositary Share stock worth more than $1,332,629,729 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Hahn may own. Additionally, Mr. Hahn receives a salary of $858,290.00 as CFO at Verona Pharma PLC American Depositary Share. Learn More about Mark W. Hahn's net worth.

How old is Mark W. Hahn?

Mr. Hahn is currently 61 years old. There are 4 older executives and no younger executives at Verona Pharma PLC American Depositary Share. The oldest executive at Verona Pharma PLC American Depositary Share is Dr. Kathleen A. Rickard M.D., Chief Medical Officer, who is 66 years old. Learn More on Mark W. Hahn's age.

What is Mark W. Hahn's salary?

As the CFO of Verona Pharma PLC American Depositary Share, Mr. Hahn earns $858,290.00 per year. The highest earning executive at Verona Pharma PLC American Depositary Share is Dr. David S. Zaccardelli Pharm.D., President, CEO & Executive Director, who commands a salary of $1,270,000.00 per year. Learn More on Mark W. Hahn's salary.

How do I contact Mark W. Hahn?

The corporate mailing address for Mr. Hahn and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Mark W. Hahn's contact information.

Has Mark W. Hahn been buying or selling shares of Verona Pharma PLC American Depositary Share?

Mark W. Hahn has not been actively trading shares of Verona Pharma PLC American Depositary Share during the past quarter. Most recently, Mark W. Hahn sold 208,912 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $2,745,103.68. Following the completion of the sale, the chief financial officer now directly owns 12,464,968 shares of the company's stock, valued at $163,789,679.52. Learn More on Mark W. Hahn's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 30 times. They sold a total of 2,932,176 shares worth more than $29,558,114.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

Mark W. Hahn Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell208,912$13.14$2,745,103.6812,464,968View SEC Filing Icon  
6/11/2025Sell400,000$11.40$4,560,000.0012,278,992View SEC Filing Icon  
5/29/2025Sell204,864$9.33$1,911,381.1212,678,992View SEC Filing Icon  
5/28/2025Sell162,704$9.30$1,513,147.2012,883,856View SEC Filing Icon  
5/27/2025Sell32,432$9.53$309,076.9613,046,560View SEC Filing Icon  
12/6/2024Sell183,728$5.01$920,477.2813,293,736View SEC Filing Icon  
12/4/2024Sell58,184$5.00$290,920.0014,117,512View SEC Filing Icon  
12/2/2024Sell1,600$5.00$8,000.0014,175,696View SEC Filing Icon  
11/29/2024Sell98,704$5.01$494,507.0414,177,296View SEC Filing Icon  
11/27/2024Sell12,936$5.00$64,680.0014,276,000View SEC Filing Icon  
11/25/2024Sell1,600$5.00$8,000.0014,289,736View SEC Filing Icon  
11/4/2024Sell80,784$4.39$354,641.7614,293,736View SEC Filing Icon  
11/1/2024Sell48,888$4.38$214,129.4414,374,520View SEC Filing Icon  
10/24/2024Sell141,360$4.38$619,156.8013,672,560View SEC Filing Icon  
10/21/2024Sell116,696$4.38$511,128.4813,973,264View SEC Filing Icon  
10/18/2024Sell249,728$4.38$1,093,808.6414,089,960View SEC Filing Icon  
8/3/2023Sell117,272$2.54$297,870.8815,679,864View SEC Filing Icon  
8/1/2023Sell105,944$2.68$283,929.9215,870,840View SEC Filing Icon  
5/1/2023Sell455,528$2.58$1,175,262.2415,976,784View SEC Filing Icon  
2/1/2023Sell413,168$2.56$1,057,710.0816,432,312View SEC Filing Icon  
8/1/2022Sell13,168$0.70$9,217.6014,913,496View SEC Filing Icon  
5/3/2022Sell12,512$0.50$6,256.0015,381,520View SEC Filing Icon  
2/2/2022Sell10,416$0.76$7,916.16View SEC Filing Icon  
11/2/2021Sell10,416$0.65$6,770.40View SEC Filing Icon  
8/2/2021Sell10,416$0.77$8,020.3216,466,800View SEC Filing Icon  
3/1/2021Sell26,728$1.14$30,469.92View SEC Filing Icon  
See Full Table

Mark W. Hahn Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows Mark W Hahn's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05